2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2814

Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 516

Microalbuminuria in Rheumatoid Arthritis: Investigating the Association with Diffuse Functional and Morphological Alterations of the Retinal Microvasculature, the Dermal Capillary Network and the Coronary Microcirculation
Abstract Number: 34

Microbiome-Drived Aberration of Hematopoietic Stem Cell Development Facilitates Immune Deregulation on the Onset of Collagen-Induced Arthritis in Mice
Abstract Number: 2018

Microenvironment Driven Re-Shaping of Pathogenic T Effector and Regulatory Subset in Active Juvenile Idiopathic Arthritic Patients
Abstract Number: 2839

Microrna Expression in the Vasculitic Skin Lesions of Adult Patients with IgA Vasculitis
Abstract Number: 1934

microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
Abstract Number: 1817

MicroRNA-128 Impairs Cartilage Integrity and Deteriorates Osteoarthritis Pathogenesis through Deregulating Chondrocyte Autophagy
Abstract Number: 2074

Micrornas Deregulation in Monocytes and T CD4 Lymphocytes from Patients with Axial Spondyloarthritis
Abstract Number: 2028

Microwave and Magnetic (M2) Myocardial Proteomics in the Mouse Model of Kawasaki Disease Demonstrates Normalization of the Proteome after Interleukin-1 Inhibition, Potential Novel Biomarkers, and Suggests New Insights into Mechanism of Disease
Abstract Number: 1449

Microwave Radiometry As a Novel Additional Method for Rheumatoid Arthritis Disease Activity Assessment: A Prospective Single-Center Study
Abstract Number: 261

Mindfulness Is Associated with Sleep Quality Among Patients with Fibromyalgia
Abstract Number: 2882

Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
Abstract Number: 1468

Minor Salivary Gland Biopsy: Its Importance in Rheumatoid Arthritis and Secondary Sjögren’s Syndrom
Abstract Number: 2840

MiR-125-b Is a Promising Biomarker for Giant Cell Arteritis in Patients with Negative Temporal Artery Biopsy Examination
Abstract Number: 1025

MiR-146a a Key Player in Bone Metabolism

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].